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Gastric carcinoma is estimated to be the second most common cancer in the world.1. The 
incidence of gastric carcinoma shows marked variations from place to place.
INDIA                -              8.9/100000 
USA                    -              10/100000
JAPAN               -               79.9/100000
ENGLAND        -               18.5/100000
These epidemiological data make it clear that gastric carcinoma incidence is determined 
by  the environmental factors.1
Incidence  of  gastric  carcinoma  stomach  in   Government  Stanley  Medical  College 
Hospital, Chennai is the following
 Year              Total number of               Ca Stomach  
                       malignancies  
2005            1117                       217
2006            1110                         210
Stomach is the commonest site for cancer in our hospital. Till recently research on the 
environmental  causes  of  gastric  carcinoma focused primarily  on diet.  The identification of 
Helicobactor pylori in chronic inflammatory conditions of the stomach has stimulated interest 
in its potential role in carcinogenesis. Infection with H.pylori is very common througout the 
world,  occurring  in  40-50% of  the  population  in  developed  countries  and  80-90% of  the 
population in developing countries.2
High  rates  of  H.pylori  infection  have  also  been  found  in  patients  with  cancer  or 
precancerous conditions (especially in chronic atrophic gastritis).
There are many cross sectional and retrospective studies  in many parts of the world 
which  give  the  causal  association  between  H.pylori  infection  and  gastric  cancer.  But  in 
Tamilnadu, where gastric carcinoma is prevalent, there are no such studies and this study is 
intended to know the association between H.pylori and subtypes of gastric adenocarcinomas 
based  on   their  degree  of  differentiation  (grading)  and  use  of  Immonohistochemistry  in 
identifying the organism, especially the coccoid forms along with Giemsa staining for H.pylori 
and to compare the efficacy of  Immonohistochemistry and Giemsa stain.
AIMS  AND  OBJECTIVES
1. To find out the incidence of H.Pylori in  gastrectomy  specimens using Giemsa stain and 
Immunohistochemistry  (IHC)  using  (polyclonal  antibody  to  H.Pylori  antigen  )  in 
patients who were operated for  growth stomach.
2.  To compare the efficacy of IHC over Giemsa stain in diagnosing H.Pylori in paraffin 
embedded tissue sections.
3. To  analyse  H.Pylori’s  association  with  respect  to   subtypes  based  on  degree  of 
differentiation of gastric adenocarcinomas.
4. To analyse H.Pylori’s association with respect to age and sex of patients and site of 
growth within stomach.
REVIEW OF LITERATURE
Gastric carcinoma is the second most common tumour in the world.Over 99% of gastric 
cancers  are  adenocarcinomas3.  Adenocarcinoma of  stomach is  primarily  a  disease  of  older 
individuals and it is rare under the age of 40 years. 
HISTORICAL REVIEW OF HELICOBACTER PYLORI:
The presence of spiral shaped microorganism was reported in 1893, by Bizzozero 4, an 
Italian pathologist in the canine stomach. Spiral bacteria 5 were demonstrated for the first time 
in human stomach in 1906. This initial report concerned patients with gastric carcinoma.
Their presence was not really taken up seriously until late 1970’s when Barry Marshell, 
a second year medical internist along with Robin Warren a histopathologist in Royal Perm 
hospital, Western Australia noted the appearance of spiral bacteria overlying the gastric mucosa 
and chiefly over the inflammed tissue.
Warren and Barry cultured these organisms in 1982 from 11 patients with gastritis.6
Originally these Camphylobacter like organisms were called Campylobacter pyloridis 
since  they  resembled  other  Campylobacters,  both  morphologically  and in  guanine-cytosine 
DNA content. For grammatical reasons, the name was changed to Campylobacter pylori7 in 
1987. 
Subsequently  it  was  shown  that  Campylobacter  pylori  did  not  belong  to  the  genus 
Campylobacter and it differs in 16 Sr RNA sequences and fatty acid content and possession of 
multiple polar (upto 7) flagella and a new genus name was suggested in 1989 by Goodwin et 
al.8 Helicobacter reflects the two morphological appearances of the organisms, helical in vivo 
and rod like in vitro.
H.Pylori  was  the  first  member  of  new  genus  and  other  Helicobacter  including  H. 
mustelae (ferrets), H.muridarum (rats and mice), H.felin (cats and dogs) etc have subsequently 
been described.
Marshall  elegantly  fulfilled  KOCH’s  postulates  9 for  the  role  of  H.Pylori  in  antral 
gastritis  with self  administration of  H.Pylori  and showed that  it  could be  cured by  use  of 
antibiotics and bismuth salts. The association between H.Pylori and peptic ulcers and possibly 
carcinoma of stomach was initially suggested by Marshall  et al.
Key dates in the history of H.Pylori:
1893 – Gastric spiral bacteria  reported for the first time in the stomach of dogs. 4
1906 – Spirochaetes are demonstrated in the human stomach. 5
1924 – Urease activity in the stomach is reported.10
1950  –  Urease  in  patients  with  gastric  ulceration  neutralizes  gastric  acid  via  the 
production of ammonia. 11
1975 – Gastric spirochaetes and gastritis present in 80% of gastric ulcer.12
1983 – Campylobacter – like organisms associated with gastritis and possibly peptic 
ulceration – beginning of modern era. 6
1985  –  Temporal  relationship  between  acquisition  of  H.Pylori  infection  and  the 
development of gastritis.9
1989 – The genus “Helicobacter”is suggested.8
1994 – H.Pylori classified as a Grade I (definite) carcinogen.13
1994 – The infection should be eradicated in patients with peptic ulcer.14
                
Many  classifications  of  gastric  carcinoma  based  on  tumour  location,  invasiveness, 
histological features, and growth patterns exist.
Classifications of  gastric carcinoma.3
Based on  invasiveness gastric carcinoma  is classified into two types as early and late. 
In  early  type,   invasion  is  restricted  to  submucosa,  which  is  further  divided  into 
intramucosal and submucosal types. In the  late type, invasion of muscularis externa is  present.
Based on the degree of  differentiation, gastric adenocarcinoma is divided into three 
types  as   Well  differentiated,  Moderately  differentiated  and  Poorly  differentiated 
adenocarcinoma. 
In  well  differentiated  adenocarcinoma,  well  developed  tubular  glands,  with  uniform 
cytological  features  are  present  (greater  than  95%  of  tumour  composed  of  glands).  In 
moderately differentiated adenocarcinoma, complex glands with cribriform change are seen 
(50-95% composed of gland).  In poorly differentiated adenocarcinoma, solid nests of cells, 
single cells, and signet ring cells with  variable cytological abnormalities  are seen. (49% or 
less composed of glands).15
This  system  is  simple  and  reproducible,  but  may  be  difficult  to  apply  because  of 
morphologic heterogeneity present in many neoplasms.
Based  on  the   histologic  features  gastric  carcinoma  is  classified  by  WHO  as 
adenocarcinoma (papillary, tubular,  mucinous, signet  ring cell),   adenosquamous, squamous 
cell carcinoma and undifferentiated  carcinoma.
Lauren has classified gastric carcinoma as Intestinal and Diffuse types.16
In Intestinal type, the incidence of  male : female ratio is  2:1 and  mean age of detection 
is 55 years. It commonly presents as an exophytic intraluminal mass with an expansile growth 
pattern as it infiltrates the wall and characterised by tubular, papillary and solid microscopic 
patterns,  with  mucin  being  restricted  to  the  glandular  lumina.The  5-year  survival  rate  is 
approximately  20%.  It  has  got  an  almost  100% association  with  intestinal  metaplasia  and 
Helicobacter pylori. Infection.3  Dietary and environmental factors are believed to be crucial to 
the development of intestinal type gastric carcinoma.3
In Diffuse type, there is  an equal sex distribution and  it  tends to occur in younger 
patients  with a mean age at  diagnosis  of  48 years.  It  commonly presents  as  an ulcerative, 
infiltrative  tumour  with  a  diffusely  infiltrative  pattern  of  growth  in  the  gastric  wall  and 
characterized microscopically by poorly differentiated, discohesive cells, often signet ring cell 
type, and often associated with intra and extracellular mucin. It has got a  poor prognosis, with 
the 5 year survival rate less than 10% and has got a lower association with intestinal metaplasia 
and Helicobacter pylori infection than  for intestinal type of gastric carcinoma. Factors in the 
causasion  of  the  diffuse  type  of  gastric  carcinoma  are  less  strongy  related  to  diet  and 
environment. Genetic factors like late mutation or altered expression of genes coding for basal 
membrane proteins, pertinent receptors or various adhesion molecules like integrins, cadherins, 
and catenins are thought to play a greater role.3,17  As with all schemes, Lauren’s classification 
is not perfect. About 10% of cases will be unclassifiable or of mixed type.
Based on the growth pattern gastric carcinoma is divided into two types by Ming as, 
Expansile and Infiltrative  types.
The expansile type of  tumours  grow as cohesive cell groups and infiltrative tumours 
have a diffusely infiltrative edge.3
Some authors have tended to equate the terms of intestinal and diffuse type of carcinoma 
with well  differentiated and poorly  differentiated tumours.  However,  this  is  misleading,  as 
some poorly differentiated carcinomas may be sharply circumscribed and intestinal in type. 
Diffuse carcinomas are usually poorly differentiated with regard to gland formation, but some 
may have low grade nuclear features. Both diffuse and intestinal types are strongly associated 
with H.Pylori infection. 18,19
Epidemiology  and Pathogenesis of Gastric cancer and precursor lesion:
Adenocarcinoma of stomach is currently the fourteenth leading cause of death in the 
world.20 It is primarily a disease of older individuals and is rare under the age of 40 years. 
Types of intestinal metaplasia:
Type I: Closely  resembles  the  morphology  of  small  intestine  with  absorptive 
enterocytes having  well  defined brush borders  and well  formed goblet 
cells. 
Type II: Incomplete metaplasia with irregular  mucous vacuoles and  absence of 
brush  borders.  Absorptive  enterocytes  are  not  easily  identified. 
Predominantly  secrete  sialomucin  and  occasionally  sulphomucin 
(abnormal mucin)
Type III: Same as type II but predominantly secrete sulphomucin.21
Molecular processes contributing to the risk to develop gastric intraepithelial neoplasia 
and adenocarcinoma with reference to Helicobacter pylori:
Chronic  H.pylori  infection  has  been  associated  with  the  development  of  gastric 
neoplasia and adenocarcinoma. Two bacterial  virulence markers of Helicobacter pylori,  the 
cytotoxin associated gene product (cag A) and the vacuolating cytotoxin (Vac A) may play a 
major role in determining the clinical outcome of Helicobacter infections.The cag A, a 120-145 
kilodalton  protein,  localized  at  one  end  of  the  cag  pathogenicity  island  (cag  PAI),  a  37- 
kilobase genomic fragment. It  contains 31 putative genes   and is associated with more severe 
outcomes.This stretch of DNA, codes for a type IV secretion (TFESS) apparatus used to inject 
bacterial protein such as CagA into host epithelial cells.20 
In addition to the widely recognized  association of  gastric cancer with the cag A+ 
genotype and phenotype of H.pylori, vacS1, and vacAm1 genotypes have also been implicated 
as markers of a particularly strong association.22   The increased risk of developing gastric 
cancer is due to  the hyperproliferation of gastric epithelial cells induced by H.pylori. In vitro 
infected epithelial cells , and in vivo studies  in humans  and animal models  have been used to 
examine bacterial factors  involved in the hyperproliferative response in the gastric epithelium.
The Cag PAI  23,24,25 and host genetic polymorphisms in the interleukin-Iβ (IL-1β) and 
IL-1  receptor  antagonist  genes  are  associated  with  overexpression  of  IL-1  and 
hypochlohydria.26,27 have  been  linked  to  an  increased   risk  of  developing  intraepithelial 
neoplasia  and intestinal type of gastric cancers.
Epithelial proliferation indices  have been  positively  correlated  with the degree of 
histological inflammation in the gastric mucosa in H.pylori infected patients 28,29,30 and  patients 
with H.pylori   negative gastritis  do not have increased  gastric epithelial cell  proliferation 
compared  to   uninfected   controls.31,32,33 A  significant  decrease  in  gastric  epithelial  cell 
proliferation has been observed following successful eradication of H.pylori.32,33
H.pylori and inflammation:
Inflammation is a critical component of tumour progression and cancer could arise from 
sites  of  infection  and  chronic  irritation.  H.pylori  is  a  genomically  diverse  pathogen34 and 
several bacterial virulence factors are considered to have a key role  on the epithelial response 
to infection. Only H. pylori genes containing the 40kb cag PAI35,36 trigger signalling cascades in 
the  gastric  epithelial  cells  resulting  in  the  release  of  proinflammatory  cytokines  and 
chemokines involved in  the immediate early response  transcription factors AP-1 and NF-
kB.37These  transcription  factors  contribute  to  the  activation  of  proinflammatory  CXC 
chemokines,  which invivo,  attract  neutrophils towards the colonized epithelium and other 
innate defences. Of particular interest has been the observation that chemokines such as IL-8 
are upregulated in gastric epithelial cells  by cag PAI positive H.pylori strains.38,39  H.pylori 
stimulates the transcription factor NF-kB which involves the activity of the kinases IKKα  and 
IKKβ.40AP-1  activation  involves   C-terminal  Janus-kinase(JNK)  activity.41 The  bacterial 
effector injected by the cag PAI type IV secretion system is peptidoglycan that is recognized by 
the intracellular  nucleotide-binding  oligomerization  domain protein (Nod1) receptor molecule 
42 which directly activates  NF-kB. Nod1 belongs  to a family that includes multiple members 
with  Nod and leucine-rich repeats  and recognizes peptidoglycan derived primarily from Gram 
negative  bacteria.41 Thus  certain  signalling cascades  that  lead to  the  activation of  the  IKK 
complex, JNK kinase and p38kinase, are only activated by H.pylori strains carrying the active 
cag PAI.43 The cag PAI  encoded Cag A protein, which is translocated into the gastric epithelial 
cell  via  the  type  IV  secretion  system,44,45,46 is  indispensable  for  H.pylori-induced  
NF-κB activation.
Activation of proliferation-Associated signalling in H.Pylori infection:
Whilst  clinical  and  animal  model  studies  have  investigated  several  aspects  of  the 
bacterial induced hyperproliferative resposes, recent in vitro studies with gastric epithelial cells 
have  begun  to  delineate  the  importance  of  specific  signalling  pathways.  Furthermore,  the 
contribution of these pathways to over expression of key genes potentially involved in gastric 
neoplasia has been examined.
The epidermal growth factor receptor (EGFR) and related EGFR ligands are thought to 
have an important role in gastric mucosal repair.  47 Studies have demonstrated that H. pylori 
activates  the  EGFR  in  gastric  epithelial  cells.48,49 The  upregulation  of  HB-EGF  gene 
transcription  by  H.  pylori  requires  metalloprotease,  EGFR  and  MEK1 activation.49 EGFR 
transactivation and increased expression of HB-EGF in gastric epithelial cells is induced by 
both cag PAI-positive and cag PAI-negative H. pylori strains.49 H. pylori infection in humans is 
associated with increased gastric mucosal levels transcripts.50 Recent in vitro studies indicate 
that H. pylori induces the receptor tyrosine kinase HER2/Neu (ErbB-2), another member of the 
EGF  receptor  family,  in  gastric  epithelial  cells.51 Gastric  expression  of  EGFR  ligands 
amphiregulin.52,53 and HB-EGF54,55 are also increased in patients with H. pylori infection and/ or 
gastric cancer. Additionally, expression of several ADAM metalloprotease disintegrin family 
genes is strongly increased in gastric cancer mucosa.56
Recent  data  show that  H.  pylori  induces  the  activation  of  c-Met  and cell  scattering 
(motogenic  response)  in  adenocarcinomatous  (AGS)  gastric  epithelial  cells.51,57   Direct 
involvement of c-Met in the stimulation of host epithelial cell motogenic response by H. pylori 
was confirmed by using small interfering RNA (siRNA) to silence the expression of the c-Met 
receptor by RNA interference (RNAi) in epithelial cells. Compared to the PAI-positive wild-
type strain, an isogenic cagA mutant strain and a virB11 mutant strain, lacking  a funtional type 
IV  secretion  system   induced  only  a  weak  motogenic  response  in  AGS  cells.51 Physical 
interaction  of  Cag  A  and  PLCγ  and  activation  of  PLC  γ  by  H.  pylori  contribute  in  the 
motogenic response. Further, MAP kinase signaling events are critical for the induction of the 
motogenic  response in  H.  pylori-infected epithelial  cells.51 The observed interaction of  the 
tyrosine phosphatase SHP-2 and phosphorylated CagA58,59 is of high interest in the context of 
H.  pylori-induced  c-Met  regulation.  Numerous  experimental  and  clinical  data  indicate  a 
particular role of Hepatocyte growth factor (HGF) and the protooncogene c-Met in tumour 
invasive growth. Thus, H.pylori-induced c-Met receptor signal transduction pathways could be 
responsible for cancer onset and tumour progression.
Based on previous studies, wild-type H. pylori strains and the cagA mutant strain could 
activate Rho GTPases Rac1 and Cdc42 in gastric adenocarcinoma (AGS) cells.60  Furthermore, 
Rac1  and  Cdc42  are  recruited  to  the  site  of  bacterial  attachment.61 Rho  GTPases  control 
polarity, protrusion, and adhesion during cell movement.62 Thus, during H. pylori infection the 
activation of Rho GTPases contribute to the motogenic response in host cells. 
As in many human tumour cells, gastric cancer  cells overexpress COX-2,63 and induce 
nitric oxide synthase.64 COX-2 and prostaglandin E2  (PGE2) are implicated in maintaining the 
function and structure of the gastric mucosa by modulating diverse cellular functions, such as 
secretion of fluid and electrolytes, and cell proliferation.65 COX-2 mRNA expression and PGE2 
synthesis in gastric epithelial cells and experimentally infected mice66 and in human gastric 
mucosa63,67,68 has been demonstrated in H. pylori infection, indicating that COX-2 is involved in 
H. pylori-related gastric pathology. H. pylori-triggered induction of the COX-2 gene appears 
independent  of  the  cag  type  IV secretion  system,  and  involves  activation  of  the  mitogen-
activated extracellular signal-regulated kinases MEK and ERK.66 A rate-limiting step in the 
control of PGE2 is the relase of arachidonic acid (AA) from membrane phospholipids, which is 
known to occur via a number of different pathways. H. pylori induces the release of PGE2 and 
AA in gastric epithelal cells by activation of the cytosolic phospholipase A2 via pertussis toxin-
sensitive heterotrimeric Gα1/Gα0 proteins and the p38 kinase. PGE2 production via AA release 
is predominately synthesized from phosphatidylinositol. In contrast to the H. pylori wild-type 
strain,  an  isogenic  strain  with  a  polar  mutation in  the  cag  PAI only  weakly  activates  AA 
synthesis.69
It  is generally accepted that H. Pylori is the cause of most cases of chronic gastritis 
followed  by  atrophy,  intestinal  metaplasia,  dysplasia  and  carcinoma.70,71,72,73,18 In  western 
countries  individuals  with  H.Pylori  infection  have  an  active  superficial  gastritis,  most 
predominant in antrum in which the organisms are easily identified (diffuse antral gastritis). 
This type of gastritis may result in duodenal ulcer probably as a result of increased basal acid 
output following a heightened parietal cell response to stimulation.74  In contrast, individuals 
infected by H.Pylori in underdeveloped countries typically have atrophic gastritis (multi focal 
atrophic  gastritis)  which  is  patchy  in  distribution  and  involves  both  pyloric  and  corpus 
mucosa.75
Organisms may be sparse in   gastritis, which is associated with  peptic ulcer, occurring 
particularly at the antrum-corpus junction along the lesser curvature.74 This multifocal atrophic 
gastritis is also associated with the development of gastric adenocarcinoma.18,75,76,77 
The contention that the pathogenesis of intestinal type of gastric cancer is a multistep 
process is supported by the observation that both atrophic gastritis and intestinal metaplasia are 
found in high incidence in patients with intestinal type of cancer and in countries with a high 
incidence of gastric cancer.78
In 1994, WHO, classified H.Pylori as grade I human carcinogens.13. Why some patients 
develop gastric atrophy while others do not progress beyond superficial gastritis is not known.79
In  superficial  gastritis,  H.Pylori  organisms  are  in  direct  contact  with  surface  and 
foveolar epithelial cells but not with cells in the glands. The bacteria are able to bind to class II 
major histocompatibility-complex molecules on the cell surfaces, inducing apoptosis.75
H.pylori induced cell cycle control and apoptosis:
Exposure  of  epithelial  cells  to  H.pylori  alters  cell  proliferation  rates  and  apoptosis 
invitro and invivo. Invitro studies have demonstrated that cyclinD1,80 expression induced in 
H.pylori infected epithelial cells is partly dependent on Cag pathogenicity island. CyclinD1 
regulates passage through  the G1 phase, and Cyclin D1 overexpression shortens  the G1phase 
and increases  the rate of cellular proliferation. CyclinD3 is frequently detected in the antral 
mucosa of H.pylori infected patients81 and Cyclin D2 over expression, together with reduced 
p27kip1 expression, are closely  associated with H.pylori infection and intestinal metaplasia.82,83 
Further, expression of  the intestine specific homeobox gene CDX2 has also been observed in 
patients with chronic gastritis and is also closely associated with intestinal metaplasia.84 CDX2 
plays  an  important  role  in  differentiation  and  maintenance  of   intestinal  epithelial  cells. 
Presumably  in  the  progression  to   neoplasia  in  the  human  gastric  mucosa,  apoptosis  in 
epithelial cells decreases but proliferation increases.
H.pylori  triggers  apoptosis  via  a  Fas  dependent  pathway,  which  depends  on  the 
expression  of  the  Cag  pathogenecity  island,85 whereas  activation  of  the  nuclear  hormone 
transcription factor peroxisome proliferators activated  receptor gamma (PPARγ) suppresses 
H.pylori  induced  apoptosis, which depends presumably on the ability of PPARγ  to inhibit 
H.pylori activation of NF-kB. Damage may be mediated by translocation of Cag A protein into 
epithelial cells.86
In  addition,  enhanced  mucosal  levels  of  interleukin,  especially  IL-8,  and  tumour 
necrosis factor are mediated through Cag-A producing strain of H.Pylori.75
H.Pylori also induces a vigorous systemic and mucosal humoral response.75 Upto 80% 
of  patients  infected  by  H.Pylori  may  have  autoantibodies  directed  against  the  canalicular 
membranes of parietal cells, or the luminal membrane of foveolar epithelium.87 Moreover, the 
canalicular  antibody  has  H+/K+  adenosine  triphosphatase  specificity.88 Damage  to  the 
epithelium may occur because of this antigenic mimicry where circulating antibodies or lamina 
propria T lymphocytes are the triggers for parietal cell destruction.
Acute gastritis due to H.pylori is rarely seen in biopsy material because the infection is 
usually either asymptomatic or accompanied only by minor gastrointestinal discomfort. The 
histological  features  include  conspicuous  pit  abscess  and exudation  of  neutrophils  into  the 
surface epithelium. This is accompanied by marked epithelial degeneration and regeneration 
which may be syncitial in type.89,90
Diffuse chronic H.pylori gastritis predominantly affects the pyloric antral mucosa, and 
although inflammatory changes are generally scanty in the corpus, organisms may be found in 
the surface mucus in all areas including the cardia. 
The mucosa shows a dense infiltrate of chronic inflammatory cells, in which plasma 
cells are especially prominent. In the corpus mucosa, any inflammation present is confined to 
the superficial zone. In the pyloric mucosa, inflammation is predominantly superficial but may 
also involve the full thickness of the mucosa and may surround and separate the glands without 
causing atrophy. Lymphoid follicles with germinal centers are usually seen, particularly in the 
deeper portion of the mucosa. This finding, which is easy to identify on low power microscopic 
examination of biopsies, is virtually pathognomonic of presence of H.pylori.91 
Evidence for the role of host genetic factors:
Host  genetic  factors  contribute   significantly  to  the  clinical  outcome  of  H.pylori 
infection There is emerging evidence of   host genetic factors that control both the host’s innate 
immune  response  and  its  inflammatory  response  against  H.pylori  infection.  There  is  an 
important interaction between these host genetic factors  and H.pylori virulence factors which 
contribute to the mucosal  damage and physiological  abnormalities  that  increase the risk of 
cancer  and  its  precursors.  In  the  the  host,  there  are  functional  polymorphisms  in  the 
interleukin-1  gene  cluster  26,27 and  tumour  necrosis  factor  alpha  genes  
(TNF-α-308)  92   which will increase the risk of non cardiac gastric cancer but not the other 
upper  gastrointestinal  malignancies,93 and the risk seems to be significantly increased in the 
presence of proinflammatory genotypes of IL-1 and of H.pylori virulence strains 21 in some 
geographical  areas.  The  risk  applies  to  both  intestinal  and  diffuse  type  of  gastric 
adenocarcinoma.94 
Pathogenesis of Helicobacter infection:
The organisms are Gram negative, slender, measuring about 0.5to0.9x2.5to3.0 μm size. 
They are seen as curved spirals in the superficial mucous layer where they tend to be attached 
to the epithelium at the site of intercellular junction.95 Genetic factors contribute significantly to 
the clinical outcome of  H.pylori  infection. There is  an important  evidence of host  genetic 
factors  that  control  both the host’s  innate immune response and its  inflammatory response 
against H.pylori infection. The interaction between host genetic factors and H.pylori virulence 
factors will contribute to the mucosal damage and physiological abnormalities that increase the 
risk of cancer and its prevalence.96
The bacteria are easily seen on H&E, if the density of organism is high. If density of 
organisms is low, Giemsa stain , Warthin Starry stain, Modified Steiner Silver stain, Acridine 
orange fluorescent stain, Leung stain,, Genta stains  97,98 Immunohistochemical methods  99  can 
be used to detect H.pylori. With the use of these techniques, H.Pylori has been found in  90% 
of patients with chronic gastritis, 95% with duodenal ulcer disease, 70% with gastric ulcer and 
50% with gastric  cancer.100 Occasionally,  following treatment  with  proton  pump inhibitory 
drugs,  H.Pylori  can be present in the stomach as coccoid forms.101 These are solid,  round, 
basophilic, dot like structures on routine histology.
Ultrastructurally,  they  are  ‘U’  shaped  with  the  ends  of  the  two  arms  joined  by  a 
membranous structure. Coccoid forms generally coexist with spiral forms but can be reliably 
identified only by specific immunohistochemical staining.102
Cultural characteristics: 
Helicobacter  pylori  produces  enzymes  like    Oxidase,  Catalse,  and   Urease.  When 
cultured on supplemented blood agar (37◦C), the colonies  usually take 3 to 5 days to appear 
and  they   are  circular  (1-2mm),  convex  and  translucent  in  appearance.  There  is  slight 
haemolysis  in  blood  agar  around  colonies  which  are  grayish  in  colour.  H.pylori  is 
microaerophillic [grow in air with enhanced Carbondioxide (10%) or mixture of CO2/O2/N2]. 
Media  for  primary  isolation  include  Skirrow’s  medium  with  vancomycin,  polymyxin  and 
trimethoprim, and  chocolate medium. 
Flagella: 
H.pylori  has  multiple  flagella  at  one  pole.  The  flagella  are  sheathed  with  a 
covering that is continuous with the outer membrane components of the body wall. The 
organisms are actively motile. The motility is  best demonstrated in broth culture. They 
exist in two forms, spiral and helical. Each flagella  is  about 30 nm diameter with a 
filament of 12-15 nm and have distinct terminal bulbs. 
Electron microscopy also reveals the presence of a 40 nm thick glycocalyx or 
capsule  like  polysachharide  rich  layer  external  to  the  cell  wall  unit  membrane.  It 
undergoes a morphological change from bacillary to coccoid form with an associated 
loss in the culturability. Coccoid form may revert to an infectious bacillary form under 
appropriate conditions. 
Biochemical characteristics:
H.Pylori produces catalase, cytochrome oxidase but is the most notable for urease 
and alkaline phosphatase activity. Typical strains are positive for alkaline phophatase, 
acid  phosphatase,  leucine  arylamidase,  naphthol  AS-B1-phophorylase  esterases.  An 
important difference between strains is their ability to produce a vacuolating cytotoxin in 
human and animal cell lines. 
Antibiotic sensitivity:
About  80% of H.pylori  are susceptible to Cephalothin (30mg disk). About 95% of 
H.Pylori are  resistant to Polymyxin B. (300 IU disk)103  and  80% of H.Pylori are resistant to 
nalidixic acid (30mg disk).
Macromolecular characteristics: 
Genomic DNA:
The  genomic  DNA  is  a  single  circular  molecule  with  a  mean  size  of  1.71  Mb 
(range-1.40 to 1.73 Mb) and with a base composition in the range of 35-37 mol% ( G+C).
Fatty acid composition:
The major cellular fatty acids are tetradecanoic and cis- 11,12 methylene octadecanoic 
and  with  smaller  amounts  of  hexadecanoic  acid  and  3  hydroxy  decanoic  acid.  The  main 
respiratory  quinine  is  Menaquinone-b  (MK-6).  Extrachromosomal  DNA-  plasmid  DNA  is 
present in about 45% of the strains.
Lipopolysaccharide (LPS):
The lipopolysaccharides express Lewis and Y group antigens.
H.Pylori- virulence faqctors: Role of Cag A and Vac A
Among people infected with H.Pylori, the virulence of the infecting strain is a major 
determinant  of  development  of  the   disease.  Strains  producing  Vaculolating  cytotoxin  A 
activity (vacAs1,vacAm1 genotypes),22 are more commonly isolated from people with peptic 
ulcers than without it.104,105 Infection with strains possessing cytotoxin associated gene product 
A (Cag A) is more common among people with peptic ulceration and gastric adenocarcinoma 
than   without it.23,106
Cag A is the marker for Cag A pathogenecity island, which includes genes necessary for 
the enhanced inflammation induced by pathogenic strain.  Serological  detection of  infection 
with Cag A+ strains is at present the best potential test for virulence. However, before strategy 
of screening and selective treatment can be considered, it is important to assess whether Cag A-
ve strains are entirely non pathogenic.
Other genteric determinants implicated in the virulence of H.Pylori are Flagellin genes 
(fla A, fla B), Urease gene cluster, Ure A, and Ure B which  encode structural subunits, Ure 
E,F,G,H and I for urease activity, Pic B which  induces  the production of IL-8 by gastric 
epitheial cells.
Epidemiology of Helicobacter pylori : 95
Epidemiology of H.Pylori infection has been extensively studied worldwide especially 
in USA, UK and orientals.  The prevalence of H.pylori in otherwise healthy individuals varies 
depending upon age,  socioeconomic  class,  and  country  of  origin.  The  infection  is  usually 
acquired in childhood.  In  developing countries  children are typically  infected by 10 years, 
whereas in developed countries there is an age related increase in prevalence. 
Age:
Most H.Pylori infections occur in childhood and in developing countries many children 
are infected by the age of 10 years. Since most adults have already acquired the infection in 
childhood, only about 0.3 – 0.5% of adults develop new infections each year.95   
Socioeconomic status:
Low Socioeconomic status is the major risk factor (especially in childhood) and close 
personal contact, overcrowding, poor sanitation are risk factors.
Genetic factors:
Recent studies of twins and children of different races suggest a genetic predisposition 
to H.Pylori95 .
Sex:
Seroprevalence is often similar in males and females.
Occupation:
Increased H.Pylori seropositivity has been seen in gastroenterologists and endoscopists. 
Submariners showed  a higher rate of H.Pylori. seropositivity than in other military groups.95  
H.Pylori habitat and mode of spread:
Natural Habitat is human stomach especially in the mucous secreting epithelium 
of the gastric antrum.
Other sites:
Areas of gastric metaplasia and ectopic gastric mucosa in other parts of GIT. H.Pylori 
has been detected in dental plaque, saliva and faeces by PCR.
Mode of survival of H.Pylori in the gastric antrum:
The bacteria live in and beneath the mucous layer that covers the gastric mucosa. The 
ability of H.pylori to bind specifically to gastric type epithelium is termed Tissue tropism, a 
property that prevents the organism from  being shed during cell and mucous turnover. Tight 
attachment  of  the  fibrillar  adhesion  on  the  bacterium to  the  carbohydrate  receptor  on  the 
mucosal cell results in the formation of attaching-effacing lesion (adherence pedestal) which 
inturn leads to actin polymerization and possibly epithelial cell distruption.95   
           It colonises the surface of the gastric mucosa and may 
extend into the gastric glands. Spiral shape and motility 
enables  it to resist peristalsis. The enzyme urease produced 
by the organisms converts urea to ammonia which enables 
the organisms to survive in the mucosa despite the high 
acidity of the lumen. The micro-aerophilic nature of the 
organism is suited to the environment of the mucosal gel and 
specific adhesions produced by the organisms are 
responsible for long-term  survival.
Transmission:95 .
Potential transmission is mainly by man
1. Faeco-oral 
2. Oral – oral
3. Gastro-oral.
Faeco –oral transmission:
Isolation  of  H.Pylori  DNA  from  faeces  and  from  drinking  water  by  PCR  analysis 
supports this mode of transmission.
Oral-oral transmission:
Evidence of isolation of H.Pylori from dental plaque and saliva by culture and PCR 
supports this mode of transmission.
Gastro-oral transmission:
This may be common in children where reflux and vomiting are common. A physician 
became infected with H.Pylori after giving mouth-mouth resuscitation to a H.Pylori +ve patient 
who had recently vomited  95. Iatrogenic person-person transmission via endoscopes has been 
reported and high prevalence of infection among endoscopists particularly those who do not 
use gloves, suggests that transmission occurs through instruments contaminated with the gastric 
secretions.95
H Pylori & Gastric cancer:
Gastric  cancer  is  the  cause  of  more  than  7,50,000  deaths  annually.   Recently,  the 
importance of H.Pylori has been recognized. The IARC (International Agency for Research on 
Cancer) has accepted H.Pylori as Grade I human carcinogen based on ecological correlation 
studies such as Eurogast study and other case-control studies.107
As the infection is rarely self limiting, it initiates sequence of inflammatory mediated 
changes within the gastric epithelium causing first acute and then chronic gastritis. And over a 
period of decades,  it  causes  increasingly degenerative changes and evolution towards well 
established precancerous condition of atrophic gastritis, metaplasia and dysplasia, in case of 
intestinal type of gastric cancer. Currently, it  remains uncertain whether the diffuse type of 
gastric cancer follows a similar histopathogenesis. One recent estimate shows that 53% and 
60% of gastric cancers in the developing and developed world respectively can be attributed to 
H.Pylori.
Genetic factors for gastric cancer:
Most  common  genetic  abnormality  found  in  gastric  cancer  tends  to  be  loss  of 
heterozygosity [LOH] of tumour suppressor gene p53. Initial studies found that LOH (60-70%) 
and mutation (38% to 70%) of p53 gene are quite common in gastric cancer. In addition, p53 
mutations are also present in intestinal metaplasia (38%) and gastric dysplasia (58%)108. Further 
evidence for the role of p53 in the early stages of gastric cancer comes from studies in mice, 
which  are  homozygous  for  p53,  which  exhibit  an  increased  proliferative  response  to 
Helicobacter infection compared with wild type mice.109. Increased proliferation has generally 
been shown to correlate with an increased risk of developing gastric cancer.31
Gastric carcinogensis – Hypothetical sequence:
The  proposed  multistep  pathway  in  the  pathogenesis  of  gastric  cancer  shows  that 
infection  with   H.pylori  may  be  a  common  initiating  event,  whereas  genetic  alterations 
(p53,APC/Beta  catenin pathway) or  Microsatellite  instability  may play a  role.  Thin arrows 
represent steps that are potentially reversible.95
       The overall survival rates for gastric cancer are poor and depend on the stage of disease at 
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the  time  of  presentation.110 In  Japan  where   small  intramucosal  lesions  can  be  detected 
endoscopically  during  screening  examinations,  trans  endoscopic  gastric  mucosal  resections 
result in improved survival.111 Unfortunately these types of aggressive screening and prevention 
programs are not universal and the disease typically presents at later stages, resulting in a poor 
prognosis with overall 5 year survival rates of less than 25%. Surgical resection is the only 
curative approach for advanced gastric cancer. A study suggests that adjuvant chemotherapy  is 
beneficial in those patients who undergo a curative resection.20 However the median survival 
for these patients  still remains less than 4 years. Thus it is clear that prevention  is the best 
overall approach to the treatment of gastric malignancy. 
It is now more than 10 years since the  discovery of H.pylori as a gastric carcinogen.13 
This  has  led  to  effective  eradication  strategies.  Effective  eradication  along  with  a  natural 
decrease in infection because of improved living conditions has resulted in  decling gastric 
cancer rates in Western countries, although this still remains a significant cause of morbidity 
and mortality in other parts of the world.
Gastric MALT-LYMPHOMA and H.pylori: 110
The close association between H.pylori and gastric  MALT lymphoma is beyond doubt 
and is seen in 72-98% of low grade cases. H.pylori is less commonly found in high grade 
gastric  lymphomas being seen in  71% of  cases  with concomitant  low grade component.110 
H.pylori  infection  is  only  seen  in   approximately  51%  of  individuals  with  secondary 
involvement of stomach by lymphoma of the nodal type.110  Lehours et al has discovered that 
apart from cag A,vacAm1 and vacAs1 genotypes other virulence patterns like HopZ play a role 
in  the development  on gastric  B-cell  lymphoma. In  addition to histomorphological  studies, 
recent epidemiological,32,20 molecular, biological and   experimental  data clearly indicate that 
H.pylori plays a decisive role in the development and progression of gastric MALT lymphoma. 
This convincing evidence inevitably involved a therapeutic effort. In 1993, Wotherspoon and 
colleagues112  reported  complete  regression  of  low  grade  lymphoma  following  successful 
eradication of H.pylori in 5 out of 6 cases. Similarly in a large prospective series of 90 cases, 
after exclusive H.pylori eradication 62% of patients showed complete regression and 12% had 
partial  remission in  a follow up period  of  12-89 months  offering a  real  chance of  cure.110 
Undoubtedly, eradication of H.pylori represents a fascinating therapeutic option because of its 
simplicity and efficacy.
H.PYLORI AND CLINICAL ASSOCIATIONS: 113
H.pylori  is  implicated  in  the  following  diseases  like  Duodenal  ulcer,  Gastric  ulcer, 
Gastricadenocarcinoma,  Gastric  MALT  lymphoma,  Duodenitis,  Barrett’s  oesophagus, 
Bronchiectasis, Anorexia of aging, Sudden infant death syndrome, Iron deficiency anaemia, 
Cerebrovascular  disease,  Hypertension,  Migraine,  Vomiting  of  pregnancy,  Autoimmune 
thrombocytopenic purpura, Hyperammonemia, Growth retardation, and chronic utricaria.
Methods of diagnosis of H.pylori:
Different invasive and noninvasive diagnostic tests are available for the diagnosis of 
H.pylori. Though far from an exhaustive coverage the main points of each method are given 
below.
In the Invasive method, endoscopic biopsy is done and small bits of tissue are obtained 
and they are subjected to the following tests namely, the Rapid urease test, Culture, Histology, 
and PCR.
The noninvasive tests are namely, the Antibody detection in serum, Urea breath test, and 
the Stool antigen test (HpSA test).
Rapid urease tests:
Rapid urease test is a simple biochemical test which involve placing endoscopy biopsy 
specimen into a small  amount  of  solution containing  urea,  pH indicator (phenol  red)  and 
bacteriostatic agent. If H.pylori are present, bacterial urease hydolyzes the urea and produces 
ammonia. Alkalinisation of the medium produces a colour change from yellow to pink. Results 
are read between one minute and 24 hours. The sensitivity and specificity of these methods are 
90% and  100%.95  Two other RUT are Hp test and Pyloritek-skip test. Interpretation may be 
performed within  one hour.
Culture: 
        This is not used routinely, but one major advantage is the detection of antibiotic sensitivity 
and culture is indicated when antibiotic resistance is suspected. The culture medium used is 
Brain Heart Infusion (BHI) agar supplemented with 7% lysed horse blood.
        Selective media are BHI agar supplemented with 10% sheep blood,  polymyxin B, 
Vancomycin, trimethoprim and amphotericin B and Skirrow’s selective medium. Incubation 
periods of upto 10 days are usually required in order to optimize the culture isolation rates 
especially in post treatment settings.
Histopathology:
         The gold standard for the diagnosis of H. pylori is the detection of the organism in the 
gastric biopsy specimens.







This is the most sensitive technique for the detection of microorganisms and useful for 
posttreatment  diagnosis  of  H.pylori  when  the  bacteria  may  be  very  low in  number.  False 
positive results are high due to inadequate cleaning and disinfection of endoscopes or from 
cross contamination in the laboratory.
Non Invasive tests :
Antibody detection test:
Seological tests detect the presence of H.pylori IgG antibodies, by ELISA, and LATEX 
agglutination tests. The Sensitivity is 91% and Specificity is 97%.95
The advantages  are,  that  they  are  non invasive,  inexpensive  and avoids  the  pitfalls, 
inherent in methods employing gastric biopsies or even urea breath tests.
Urea Breath Tests:
13C and 14C Urea Breath Test (UBT) – measures the activity of H.pylori urease. Patient 
ingests  13C and  14C labelled urea. If H.pylori is present in the stomach, urease hydolyses the 
labelled urea releasing labeled bicarbonate transported in blood to the lungs and exhaled as 
Carbondioxide (CO2).
The breath is collected and 13C or 14C is measured. This test is preferred in children and 
in pregnant women. It should not be used in patients who has taken Proton Pump Inhibitors, 
bismuth compounds or antibiotics.
Other assays include:
1. Detection of antibodies in the urine
2. Measurement of labelled serum bicarbonate following administration of 13 C urea 
as in UBT.
3. Measurement of 14 C in the urine
4. Measurement of 15-n labelled ammonia which is absorbed and excreted in the 
urine.              
Sensitivity of Urea Breath Test is 90% and specificity is 96%.95
Stool antigen test:
This is a rapid non invasive, easy to perform test  can be used to detect active infection, 
monitor  effectiveness during therapy and to confirm cure after  antibiotic  use.  Comparative 
accuracy, availability, and cost of tests for H.pylori infection puts the sensitivity and specificity 
of the stool antigen test as 90-95%.114
MATERIALS AND METHODS
Study design:
              The study was carried out in the  Department  of Pathology, Govt. Stanley medical 
college,  with  the  help  of  Dept.  of  Medical  and  Surgical  Gastroenterology,  Govt.  Stanley 
medical college hospital, during the period 2005 to 2007. A total of 60 gastrectomy specimens 
with  carcinoma  stomach  were  received.  Out  of  this,  a  random sample  of  50  gastrectomy 
specimens were taken for this study.
Method:
For all the 50 cases,  details of age, sex were recorded.  Depending upon the site of 
growth, the stomach was opened through the  greater or the  lesser curvature. The presence of 
growth was noted. The gross appearance and three dimentional measurement were taken. The 
site of the lesion were also taken and recorded.
Multiple bits from the lesion and the adjacent areas were taken and processed routinely 
for paraffin embedding. 4μ sections were taken and stained by H&E. Sections were further 
stained by Giemsa stain.
Sections were also mounted on chrome alum coated slides.
The neoplasm was subtyped as well differentiated, moderately differentiated and poorly 
differentiated carcinomas  under H&E.
Giemsa stained sections were used for recording the presence of Helicobacter pylori.
Sections mounted on chrome alum coated slides were used for IHC.
GIEMSA STAINING TECHNIQUE. 115
Giemsa stock solution:
Giemsa stain powder -  4 gm
Glycerol                     - 250 cc
Methanol                   - 250 cc.
The powder is dissolved in glycerol at 60◦C with regular shaking. Methanol is added, the 
mixture is well shaken and then allowed to stand for 7 days. Filter before use.
Working Giemsa stain:
Giemsa  stock  solution  - 4 cc
Buffered  distilled  water - 96 cc
Method:
1. Dewax in Xylol, hydrate through graded alcohols to water
2. Rinse in buffered distilled water (pH 6.8)
3. Stain in working Giemsa stain overnight
4. Rinse in distilled water
5. Rinse in 0.5 aqueous acetic acid until the section is pink.
6. Dehydrate, clear in xylene and mount in DPX .
Preparation of gelatin coated slides:
Chrome alum - 0.05 gm
Gelatin                         - 0.3 gm
Distilled water             - 100 ml
First chrome alum is added to distilled water and then the distilled water is heated to 
60◦C. Gelatin is added slowly to the heated distilled water. Glass slides are then dipped in this 
solution and dried  overnight.
Preparation of Tris Buffered Saline (TBS): 0.005 M TBS
Distilled water - 10 litres
Sodium Chloride           - 80 g
TRIS (Hydoxymethylamine) - 6.05 g
1 M Hcl   - 44 ml
Final pH is adjusted to 7.6 with either 1 M Hcl or 0.2 M Tris solution
Preparation of CITRATE buffer solution (antigen retrieval solution):
Trisodium citrate - 2.94 gm
1N Hcl - 5 ml
Distilled Water - 1000 ml
Final pH is adjusted to 6.0 with 1N Hcl.
Antigen Retrieval:
The slides are placed in citrate buffer in the coplin jar 
and capped. The jar is then heated in a 750 W domestic 
microwave oven for 15 minutes 
(5 minutes in low power(40), 5 minutes in medium power(60) 
and 5 minutes in full power(80) pausing only to top up the 
fluid.
Procedure adopted for IHC:116
1. Dewax the sections in xylene (1/2 hour, two changes)  and bring sections to distilled 
water.
2. Antigen retrieval using TBS by Microwave oven heating
3. Cool to room temperature in running tap water for 20 minutes.
4. Bring sections to TBS for 5 minutes.
5. Drain and wipe off excess TBS around sections
6. Incubate in endogenous peroxidase blocking reagent for 15-20 minutes
7. Gently wash the slides in TBS for 5 minutes.
8. Wipe off the excess fluid and Incubate in power block for 15-20 minutes.
9. Wipe the excess fluid and incubate  in  Primary Antibody for 60 minutes
10. Repeat steps 4 and 5
11. Incubate in super enhancer  for 30 minutes
12. Repeat steps 4 and 5
13. Incubate in S S label (secondary antibody) for 30 minutes
14. Repeat steps 4 and 5
15. Incubate in DAB (Diaminio Benzidine) substrate solution for 2-10 minutes
(To prepare DAB substrate, add 1ml of Substrate buffer, 
1 drop of liquid DAB, and 1 drop of Substrate DAB).
Wash in distilled water, counter stain with Haematoxylin, clear in xylene and mount with DPX.
RESULTS AND OBSERVATION
The collected details of cases have been recorded in the master chart. All collected data 
were analyzed and following results were observed
H.pylori in carcinoma stomach patients:
Table - 1
Total number of patients included in the study was 50.Out of 50 patients, 25 patients 
were Helicobacter pylori positive and the rest of 25 patients were  H.pylori negative.
Total No. of patients H.pylori +ve H.pylori -ve
50 25 25
The  prevalence  of  H.pylori  among  patiens  who  were  diagnosed  as  adenocarcinoma 
stomach was 50% .
Male:female ratio of adenocarcinoma:
Table - 2
Out of 50 cases of adenocarcinoma stomach, 39(78%) were males and 11(22%) were 
females with a male to female ratio of 3.5:1
Total no of 
patients Males Females
50 39(78%) 11(22%)
Male:female ratio of H.pylori infection:
Table - 3
Out  of  39  male  patients,  17(43.6%)  were  H.pylori  positive  and  out  of  11  females, 
7(63.6%) were H.pylori positive.
Sex No. of patients H.pylori -ve H.pylori+ve
Male    39 22(56.4%) 17(43.6%)
Female 11 4(36.4%) 7(63.6%)
Age incidence of H.pylori:
Table - 4
The age  of the patients included in this study ranges between 30 and 75 with mean age 
of 51.75 years. The incidence of H.pylori increases with age reaching a peak between 41-50 
years which  is  statistically  significant  with  a p value of 0.033.
H.pylori
Negative Positive
n % n %
Age 31-40 2 8.0% 3 12.0%
41-50 11 44.0% 12 48.0%
51-60 7 28.0% 7 28.0%




Mean Age for Subtypes of Gastric carcinoma:
Table - 5
Most of the H.pylori +ve patients  in our study are in the age group of 41  to50 
years, with mean age of 53  years for well differentiated adenocarcinoma and   47.29 









WD 6 54.33 4.320
MD 4 48.50 10.630
PD 15 54.00 11.180





WD 11 53.00 10.894
MD 7 50.45 7.141
PD 5 47.29 9.196




WD-Well differentiated, MD-Moderately differentiated, 
PD-Poorly differentiated
H.pylori and site of growth:
Table - 6
Out of 50 cases taken for this study, 41 cases were  located in the antropyloric region 
and. Among these  41 cases, 20 cases were  positive  for H.pylori (48.8%)
Out of the 9 cases, which  were located at the body and fundus region ,5 cases were 





n % n %
Chi square 
test
Site of the 
tumour
Antrum  and 
pylorus 21 51.2% 20 48.8%
Body  and 
fundus 4 44.4% 5 55.6%




n - number of cases
H.pylori and grading of adenocarcinoma stomach:
Table -7
Out  of  25  H.pylori+ve  adenocarcinomas,  13  (52%)were  Well  differentiated,  5 
(20%)were Moderately differentiated and 7 (28%) were Poorly differentiated adenocarcinomas. 








WD 6 24% 13 52%
MD 4 16% 7 28%
PD 15 60% 5 20%




WD-Well differentiated, MD-Moderately differentiated,
PD-Poorly differentiated
In the case of 25  H.pylori –ve adenocarcinomas, about 15 cases( 60%)  were poorly 
differentiated,  4  cases(16%)  were  moderately  differentiated  and  6  cases(24%)  were  well 
differentiated. 
Detection of H.pylori with GIEMSA STAIN:
Table - 8
Out of 50 cases H.pylori was detected in 21 cases using Giemsa stain  with 42% of 
positivity.




Detection  of  H.pylori  with  polyclonal  antibodies  against  H.pylori  antigen  by  
Immonohistochemistry :
Table - 9
Out of 50 cases, IHC detected H.pylori in 25 cases  (4 cases more than   GIEMSA) with 
a positivity rate of 50%




Comparison of IHC and GIEMSA:
Table - 10
Out of 50 cases, IHC detected H.pylori in 25 cases with a positivity of  (50%) With 4 






       ESTIMATE 95%CI
SENSITIVITY                                           100%                                  83-100%
SPECIFICITY                                             86%                                  68-96%
POSITIVE PREDICTIVE VALUE            84%                                  63-95%
NEGATIVE PREDICTIVE VALUE         100%                                86-100%
k agreement status                               k=0.84 and p=0.001
According to the TWO SAMPLE BINOMIAL PROPORTION TEST, 
Z=0.60 and p=0.55
Eventhough statistically there is no difference between IHC and GIEMSA stains, it can be 
said that upto 29% positivity can be expected more in IHC than in GIEMSA stain. 
DISCUSSION
Histological  type influences  the   prognosis  of  gastric  carcinoma.  Well  differentiated 
adenocarcinoma and intestinal type of Lauren have the best prognosis and poorly differentiated 
and diffuse type of Lauren with signet ring cells have the worst prognosis.3. The main aim of 
this study is to  know the assiciation  between H.pylori and the subtypes  of gastric carcinoma 
(grading) and to confirm the causal relationship between  H.pylori and gastric carcinoma, and 
use  of  Immunohistochemistry  in  diagnosing H.pylori  in  paraffin  embedded tissue sections, 
along  with Giemsa stain.  Three nested case control  studies had shown that infection with 
H.pylori increases the risk of gastric cancer.(Loin et al116, Parsonet et al106, Nomura et al 117.  A 
combined analysis of these studies  has estimated that 73% of gastric cancers are attributable to 
H.pylori in those who have been infected for over 14 years.
In this study, the percentage of H.pylori positivity in gastric malignancy is 50%. The 
prevalence of H.pylori among patients who were diagnosed as adenocarcinoma stomach was 
50%  which correlates with Robey- Cafferty SS et al118, 1989. 
The Male : female ratio of adenocarcinoma in our study is 3.5:1.                 Okusa et al 
119   says that his study  has male dominance  with male : female ratio  of 4.7:1
Most of the H.pylori +ve patients  in this study were in the age group of  41 to 50 years, 
with mean age of 53 years for well differentiated adenocarcinoma and   47.29   years for poorly 
differentiated adenocarcinoma which coincides with with  Enrico solcia et al where the mean 
age(51.9years) of poorly differentiated adenocarcinoma is lower than that of well differentiated 
adenocarcinoma.(64.5 years)  17.  The incidence of H.pylori increases with age reaching a peak 
between 41-50 years which is statistically significant with a p value of 0.033  whereas in the 
study of  Loin et al 116 in which peak age incidence of H.pylori is 60 years.
The location of adenocarcinoma in antropyloric region is 82% (41 out of 50cases) and in 
the body and fundus region it is 18% (9 out of 50 cases). Though statistically not significant, 
H.pylori is associated more with adenocarcinoma  located at body and fundus region, ie, in 5 /9 
cases(55.6%) than   tumours located in  antropyloric location, ie,  in 20/41 cases(48.8%).
Out of 25 H.pylori +ve cases, it is most commoly associated with well differentiated 
adenocarcinoma  with  68.4%(13/25  cases)  and  least  commonly  associated  with  poorly 
differentiated aenocarcinoma with 20%  (5/25 cases) which is statistically significant, with p 
value of 0.05.
Whereas  in the 25 H.pylori –ve  cases of adenocarcinoma, about 15 out of 25 cases 
(60%) were poorly differentiated adenocarcinomas and only  6 out of 25 cases were (24%) 
well differentiated  adenocarcinomas, implying that genetic factors could play a major role in 
the pathogenesis of poorly differentiated adenocarcinoma.120.
When compared with Giemsa stain, Immunohistochemistry has detected 4 cases more 
(25/50) with a sensitivity of 100% and specificity of 86% and a positive predictive value of 
84% and a negative predictive value of 100% and accuracy rate of 92%.
The k agreement status(k=0.84 and p=<0.001) is correlating  between                        the 
two methods.  In  this  study, out of 39 males,17(43.6%) were H.pylori  +ve,  and out of  11 
females, 7 (63.6%) were H.pylori +ve implying that  H.pylori infection is a significant risk 
factor for  adenocarcinoma in women more than in men which coincides with Julie Parsonnet et 
al  120   which  says  that  H.pylori  is  +ve   in  90.9%  in  females  and  81.6  %  in  males  of 
adenocarcinoma stomach.
Epidemiological  studies  have  consistently  demonstrated  an  association 
between Helicobactor pylori infection and the risk of gastric cancer.An analysis                     of 
data from 13 countries  showed a strong correlation between the incidence                       of 
gastric cancer and the prevalence of H.pylori infection107. Prospective                     serologic 
studies have reported that persons wih H.pylori infection have a three                      to six fold 
higher risk of gastric cancer than the normal persons.122. This                      association seems 
largely restricted to intestinal type and well                     differentiated adenocarcinomas and 
cancers  of  distal  stomach.  Because   Helicobacter  pylori  infection  appears  to  be  the  most 
consistent factor in gastric cancer induction,  the effects of H.pylori treatment on modulation of 
gastric  cancer risk  has been evaluated extensively 20.
It has been found that gastric mucosal  proliferation is decreased following  successful 
treatment thereby presumably decreasing  the frequency of mutation events associated with 
carcinogenesis.33,120. Eradication of H.pylori has been demonstrated to be cost effective  as a 
preventive therapy for gastric cancer if it prevented atleast 30% of cancers.20.
In limited studies, H.pyloyi eradication  has been suggested to prevent progression and 
may lead to regression of precursor lesions, such as atrophy.122 It has also been suggested that 
H.pylori eradication in patients who have had endoscopic mucosal resection of early gastric 
cancer can reduce recurrent cancers20. A randomized trial was conducted in Colombia and a 
beneficial effect of H.pylori eradication on atrophy and intestinal metaplasia was observed after 
6 year follow up period 123.
In a  clinical trial in China, patients with persistent infection had a 2.1%                risk of 
progression of intestinal metaplasia, whereas H.pylori eradication               therapy reduces the 
risk of progression of intestinal metaplasia significantly.124.
The recent data of effects of H.pylori eradication on precancerous lesions as well as the 
reduced risk of gastric cancer development strongly support early H.pylori therapy. H.pylori 
eradication with appropriate antibiotic treatment  should be considered in future  to prevent 
malignancy in H.pylori  +ve subjects who are  at risk for gastric cancer. (members  of gastric 
cancer families).
Screening of gastric cancer patients in asymptomatic persons increase the chance of 
detecting early cancer and hence may improve overall survival.
Gastric cancer-A PREVENTABLE DISEASE:
H.pylori infection can thus be considered as a substantiative cause of gastric cancer. In 
H.pylori infection , a stage is reached in which H.pylori is no longer required in the progression 
of events  leading to carcinoma. That is,  a point  of no return  is reached and carcinogenesis 
can proceed  autonomously. So eradication therapy should be started very early at a younger 
age in order to prevent gastric cancer.
Hence for cancer prevention, asymptomatic individuals should be  tested for H.pylori 
infection and H.pylori  positive  patients should be treated. (TEST AND TREAT policy).96.
Test and treat policy  is a large scale project , which is clearly expensive and would  not be 
economically cost effective in population where the prevalence rate of gastric cancer in low 
socioeconomic  group  is high as in India and Japan. An important priority therefore to be given 
over the coming years   to conduct  intervention studies and produce the necessary evidence 
and thereby  prevent  gastric cancer which is one of the  world’s major cancers.
SUMMARY AND CONCLUSION
Fifty  gastrectomy specimens of carcinoma received at  the Department of  Pathology, 
Stanley Medical College were analysed. 
Age, sex and site of the lesion were recorded
Subtyping of carcinoma was done
Giemsa staining was used for detecting Helicobactor pylori
Immunohistochemistry using polyclonal antibodies against  H.pylori  antigen was also 
done to assess the role of immunohistochemistry in detection of H.pylori.
Results were tabulated and analysed.
H.pylori  was  positive  in  21  out  of  50  cases  as  per  Giemsa   and  by  doing 
Immunohistochemistry 25 out of  50  cases .
The study revealed the following facts:
1. The peak incidence of adenocarcinoma stomach is between 41 to 50 years with a  male : 
female ratio of 3.5:1
2. The peak incidence of H.pylori positivity in gastric carcinoma is between 41 to 50 years.
3. H.pylori  is  associated  more  with  well  differentiated  adenocarcinoma  than  poorly 
differentiated adenocarcinoma of stomach.
4. H.pylori is associated in 52% of well differentiated adenocarcinoma, with mean age of 
53.45 years,  28% of moderately differentiated adenocarcinoma with mean age of 50 
years, and 20% of poorly differentiated adenocarcinoma  with mean age of 47.23 years. 
5. Sensitivity of Immunohistochemistry is more when compared            with   Giemsa.
6. Immunohistochemistry can be used to detect coccoid forms of H.pylori especially in 
screening for the presence of H.pylori in high risk patients and also in patients 
who had been treated  with  proton pump inhibitors and to confirm eradication 
following antibiotics against H.pylori.
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